Protein modifications like methyl groups have critical roles to play in switching proteins on or off, or completely rewiring their networks. The analysis of these modifications in research labs and clinical testing centres is challenging. These methyl groups are chemically subtle, occur in tiny amounts, and there is no universally accepted method for doing the analysis. The goal of this proposal is to adapt a new family of binding chemicals—currently used in industrial applications—that can selectively bind methylated proteins. The investigators will demonstrate that these agents can operate within normal protein analysis (proteomics) workflows, are highly reproducible and their performance from batch-to-batch and lab-to-lab are intrinsically superior to those of antibodies. This technology should transform methylation research, lead to new medicines and diagnostics, and drive sales, new jobs, and new science in research labs and diagnostics centres.